Bryony Dawkins

1.4k total citations · 1 hit paper
24 papers, 599 citations indexed

About

Bryony Dawkins is a scholar working on Oncology, Economics and Econometrics and General Health Professions. According to data from OpenAlex, Bryony Dawkins has authored 24 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Economics and Econometrics and 5 papers in General Health Professions. Recurrent topics in Bryony Dawkins's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Global Maternal and Child Health (4 papers). Bryony Dawkins is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Global Maternal and Child Health (4 papers). Bryony Dawkins collaborates with scholars based in United Kingdom, Norway and South Africa. Bryony Dawkins's co-authors include Richard Cookson, Miqdad Asaria, Andrew J. Mirelman, Anthony J. Culyer, Susan Griffin, Stéphane Verguet, Ole Frithjof Norheim, David Meads, David Jayne and Bethany Shinkins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Bryony Dawkins

19 papers receiving 592 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

2021 152 citations Kate Absolom, Lorraine Warrington et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Bryony Dawkins

Since Specialization

Citations

This map shows the geographic impact of Bryony Dawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryony Dawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryony Dawkins more than expected).

Fields of papers citing papers by Bryony Dawkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryony Dawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryony Dawkins. The network helps show where Bryony Dawkins may publish in the future.

Co-authorship network of co-authors of Bryony Dawkins

This figure shows the co-authorship network connecting the top 25 collaborators of Bryony Dawkins. A scholar is included among the top collaborators of Bryony Dawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryony Dawkins. Bryony Dawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inequities in Household Out-Of-Pocket Spending Among Urban Slum Dwellers in Southeast Nigeria 2025 ·International Journal of Public Health ·(unknown), (unknown), (unknown), Aloysius Odii, Joseph Paul Hicks, (unknown), Uchenna Ezenwaka, Bryony Dawkins, Obinna Onwujekwe	0
2	Evaluating Access Improving Interventions: An Economic Evaluation of Surgical Task-Shifting for C-Sections in Sierra Leone 2025 ·Applied Health Economics and Health Policy ·Bryony Dawkins, Bethany Shinkins, Tim Ensor, David Jayne, (unknown), Alex J. van Duinen, Håkon A. Bolkan, David Meads	0
3	Cost-Effectiveness of eRAPID eHealth Intervention for Symptom Management During Chemotherapy 2024 ·JCO Oncology Practice ·Bryony Dawkins, Kate Absolom, Jenny Hewison, Lorraine Warrington, (unknown), Patricia Holch, Robert Carter, Andrea Gibson, (unknown), Zoe Rogers, Sarah Dickinson, Carolyn Morris, (unknown), Julia Brown, Claire Hulme, Galina Velikova	0
4	Patient and clinician perspectives of an eHealth intervention for supporting cancer treatment in the UK: mixed methods evaluation of the eRAPID randomised controlled trial 2024 ·BMJ Open ·Lorraine Warrington, (unknown), Andrea Gibson, Rosemary Peacock, Zoe Rogers, Sarah Dickinson, Patricia Holch, Jenny Hewison, Claire Hulme, Bryony Dawkins, (unknown), (unknown), (unknown), Julia Brown, Galina Velikova, Kate Absolom	0
5	Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines 2024 ·International Journal of Technology Assessment in Health Care ·Bryony Dawkins, Bethany Shinkins, Tim Ensor, David Jayne, David Meads	0
6	Cost-effectiveness of gasless laparoscopy as a means to increase provision of minimally invasive surgery for abdominal conditions in rural North-East India 2022 ·PLoS ONE ·Bryony Dawkins, (unknown), Tim Ensor, Jesudian Gnanaraj, Julia Brown, David Jayne, Bethany Shinkins	1
7	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results 2022 ·Blood Cancer Journal ·Holger W. Auner, Sarah Brown, Katrina Walker, (unknown), Bryony Dawkins, David Meads, Gareth J. Morgan, Martin Kaiser, Mark Cook, (unknown), Christopher Parrish, Gordon Cook	10
8	Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy breakdown → 2021 ·Journal of Clinical Oncology ·Kate Absolom, Lorraine Warrington, (unknown), Jenny Hewison, Carolyn Morris, Patricia Holch, Robert Carter, Andrea Gibson, (unknown), Beverly Clayton, Zoe Rogers, Lucy McParland, Mark Conner, Liz Glidewell, (unknown), Bryony Dawkins, Sarah Dickinson, Claire Hulme, Julia Brown, Galina Velikova	152
9	Training programme in gasless laparoscopy for rural surgeons of India (TARGET study) - Observational feasibility study 2021 ·International Journal of Surgery Open ·(unknown), Jesudian Gnanaraj, (unknown), Manish Chauhan, Aaron Quyn, Anurag Mishra, Lovenish Bains, Ginimol Mathew, (unknown), Bonnie Cundill, (unknown), (unknown), Bryony Dawkins, Bethany Shinkins, Julia Brown, David Jayne	6
10	What factors affect patients’ ability to access healthcare? An overview of systematic reviews 2021 ·Tropical Medicine & International Health ·Bryony Dawkins, (unknown), Tim Ensor, Bethany Shinkins, David Jayne, David Meads	110
11	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor 2020 ·Trials ·Samantha Hinsley, Katrina Walker, (unknown), Lucy Bailey, (unknown), Louise Flanagan, (unknown), (unknown), Bryony Dawkins, David Meads, Holger W. Auner, Martin Kaiser, Mark Cook, Sarah Brown, Gordon Cook	3
12	What factors affect patients’ access to healthcare? Protocol for an overview of systematic reviews 2020 ·Systematic Reviews ·Bryony Dawkins, (unknown), Tim Ensor, Bethany Shinkins, David Jayne, David Meads	7
13	Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy 2020 ·Acupuncture in Medicine ·Alex Molassiotis, Bryony Dawkins, Roberta Longo, Lorna Kwai Ping Suen, Huilin Cheng, Tony Mok, Claire Hulme, Winnie Yeo	4
14	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa 2019 ·Value in Health Regional Issues ·Abualbishr Alshreef, (unknown), Bryony Dawkins, (unknown), Sue Ward, David Meads, Matthew Taylor, Simon Dixon, Anthony J. Culyer, Francis Ruiz, Kalipso Chalkidou, Ijeoma Edoka	11
15	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT 2019 ·Health Technology Assessment ·Mark T. Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire Hulme, Anna C. Whittaker, Peter M. Hawkey, Eric Low, Janet Dunn	4
16	Reducing Antibiotic for Child Upper Respiratory Infections in Rural China: An RCT, Process Evaluation and Cost-Effectiveness Analysis 2018 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·(unknown), (unknown), John Walley, Joseph Paul Hicks, Bryony Dawkins, Jingyu Zeng, (unknown)	1
17	Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries 2018 ·Value in Health ·Abualbishr Alshreef, (unknown), Bryony Dawkins, (unknown), Sue Ward, David Meads, Matthew Taylor, Simon Dixon, (unknown), (unknown), Francis Ruiz, Kalipso Chalkidou, Joanne Lord, Ijeoma Edoka	2
18	Cost‐effectiveness analysis of a multi‐dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China 2018 ·Tropical Medicine & International Health ·Zhitong Zhang, Bryony Dawkins, Joseph Paul Hicks, John Walley, Claire Hulme, Helen Elsey, Simin Deng, Mei Lin, Jun Zeng, Xiaolin Wei	20
19	Using Cost-Effectiveness Analysis to Address Health Equity Concerns 2017 ·Value in Health ·Richard Cookson, Andrew J. Mirelman, Susan Griffin, Miqdad Asaria, Bryony Dawkins, Ole Frithjof Norheim, Stéphane Verguet, Anthony J. Culyer	197
20	Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia 2017 ·Health Policy and Planning ·Bryony Dawkins, Andrew J. Mirelman, Miqdad Asaria, Kjell Arne Johansson, Richard Cookson	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact